AGL 40.02 Increased By ▲ 0.01 (0.02%)
AIRLINK 178.07 Decreased By ▼ -19.78 (-10%)
BOP 9.96 Decreased By ▼ -0.41 (-3.95%)
CNERGY 6.94 Decreased By ▼ -0.19 (-2.66%)
DCL 10.09 Decreased By ▼ -0.52 (-4.9%)
DFML 41.57 Decreased By ▼ -2.25 (-5.13%)
DGKC 106.89 Increased By ▲ 1.22 (1.15%)
FCCL 39.03 Decreased By ▼ -0.57 (-1.44%)
FFBL 81.89 Increased By ▲ 1.64 (2.04%)
FFL 13.70 Decreased By ▼ -0.44 (-3.11%)
HUBC 119.25 Decreased By ▼ -1.31 (-1.09%)
HUMNL 14.00 Decreased By ▼ -0.67 (-4.57%)
KEL 5.91 Decreased By ▼ -0.25 (-4.06%)
KOSM 8.06 Decreased By ▼ -0.20 (-2.42%)
MLCF 48.10 Decreased By ▼ -1.51 (-3.04%)
NBP 72.83 Decreased By ▼ -1.65 (-2.22%)
OGDC 193.76 Decreased By ▼ -3.31 (-1.68%)
PAEL 32.15 Decreased By ▼ -2.95 (-8.4%)
PIBTL 8.02 Decreased By ▼ -0.50 (-5.87%)
PPL 174.07 Decreased By ▼ -2.19 (-1.24%)
PRL 32.60 Decreased By ▼ -0.66 (-1.98%)
PTC 25.27 Decreased By ▼ -0.32 (-1.25%)
SEARL 124.96 Increased By ▲ 3.92 (3.24%)
TELE 9.42 Decreased By ▼ -0.48 (-4.85%)
TOMCL 35.39 Increased By ▲ 0.16 (0.45%)
TPLP 11.62 Decreased By ▼ -1.12 (-8.79%)
TREET 18.42 Decreased By ▼ -0.55 (-2.9%)
TRG 60.49 Increased By ▲ 0.21 (0.35%)
UNITY 38.21 Decreased By ▼ -0.81 (-2.08%)
WTL 1.66 Decreased By ▼ -0.17 (-9.29%)
BR100 11,535 Decreased By -214.8 (-1.83%)
BR30 35,550 Decreased By -621.5 (-1.72%)
KSE100 108,897 Decreased By -1073.7 (-0.98%)
KSE30 33,809 Decreased By -321.9 (-0.94%)

NEW YORK: A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.

The two pharmaceutical giants said they intend to appeal the decision, which concluded that the companies engaged in unfair and deceptive business practices.

The state of Hawaii alleged the companies misled consumers about the benefit of using the drug, particularly for people of East Asian ancestry.

The drug makers “intend to appeal the trial court’s decision and we are confident in our success on appeal,” the companies said.

The state pointed to results showing the treatment did not work well for some patients of Asian or Pacific-island descent who could not properly metabolize the drug, according to the reports.

But the two companies disagreed, saying, “Leading cardiologists have examined the scientific evidence and continue to recommend Plavix as the standard of care for all its indications regardless of race or ethnicity.

Comments

Comments are closed.